Tumor suppressor p53 has been shown to repress expression of vascular endothelial growth factor (VEGF), an endothelial cell-speci®c mitogen and a key mediator of tumor angiogenesis. The p63 gene, recently identi®ed as a p53-relative, encodes multiple isoforms with structural and functional similarities and dierences from p53. In this study, we show the evidence that the two major isoforms of the p63 gene, TAp63g (p51A) and dNp63a (p73L), represses and upregulates VEGF expression, respectively, on transcription and protein levels. Transient transfection assays show that a hypoxia-inducible factor (HIF) 1 binding site within the VEGF promoter region is responsible for both upregulation and repression by dNp63a and by TAp63g, respectively, of the VEGF promoter activity. We also show that TAp63g targets HIF1a for promoting proteasomal degradation but that dNp63a targets HIF1a for stabilization. Mammalian two-hybrid assays show that HIF1a-dependent transcription is repressed by TAp63g as well as by p53, whereas it is upregulated by dNp63a in collaboration with a transcription coactivator p300. Our data also show that dNp63a acts as a dominant-negative reagent toward both p53-and TAp63g-mediated degradation of HIF1a and repression of HIF1a-dependent transcription. These results suggest that p63 is involved in the regulation of the VEGF gene expression and that modulation of VEGF expression by TAp63g and dNp63a is closely correlated with their distinct roles on the regulation of HIF1a stability.
Introduction
Vascular endothelial growth factor (VEGF) has been described as a key mediator of angiogenesis and neovascularization (Martiny-Baron and Marme, 1995) . The VEGF mRNA is expressed predominantly in tumor cells and stromal cells, whereas the mRNA for the VEGF receptors is expressed and upregulated in tumor endothelial cells (Suzuki et al., 1996) . This expression pro®le hypothesizes the VEGF to be a primary paracrine regulator of tumor angiogenesis. Several groups have shown that VEGF expression is induced by exposing cultured cells to 1% O 2 , CoCl 2 or desferrioxamine, and induction can be blocked by treating hypoxic cells with cycloheximide (Gleadle et al., 1995; Goldberg and Schneider, 1994; Shweiki et al., 1992) . Recent studies have demonstrated that hypoxia increases VEGF transcription in several dierent cell types (Finkenzeller et al., 1995; Ikeda et al., 1995; Levy et al., 1995; Liu et al., 1995) . Thus, transcriptional control of the VEGF mRNA might be one of the major steps that regulate VEGF expression.
Hypoxia-inducible factor 1 (HIF1) is a heterodimeric transcription factor that regulates transcription of several genes involved in oxygen homeostasis (Wenger and Gassmann, 1997; Semenza, 1998 Semenza, , 1999 . HIF1 consists of two subunits, HIF1a and HIF1b (ARNT (aryl hydrocarbon receptor nuclear translocator)), which belong to a subfamily of basic helix ± loop ± helix ± PAS domain (bHLH ± PAS) transcription factors (Wang et al., 1995) . While hypoxia prevents proteasomal degradation of HIF1a, the expression of HIF1b is thought to be oxygen-independent (Huang et al., 1998; Kallio et al., 1999; Salceda and Caro, 1997) . The binding of HIF1a to the target DNA site, in conjunction with HIF1b, leads to transcriptional activation of the downstream genes including the VEGF gene. The studies on HIF1a-de®cient mice have suggested a key role of HIF1a on the VEGF-mediated angiogenesis in response to hypoxia (Iyer et al., 1998; Kotch et al., 1999) . In supporting this notion, both HIF1a and VEGF are overexpressed in a wide variety of human cancers (Folkman, 1997; Zong et al., 1999) .
The tumor suppressor p53 is suggested to have a negative role on VEGF expression (Bouvet et al., 1998; Fontanini et al., 1998; Mukhopadhyay et al., 1995) . At the molecular level, it has been shown that p53 inhibits HIF1 activity by targeting the HIF1a subunit for ubiquitination and proteasomal degradation (Ravi et al., 2000) . Conversely, both loss of p53 and forced expression of HIF1a in p53-expressing tumor cells have been shown to augment VEGF expression in response to hypoxia (Ravi et al., 2000) . In this point of view, it is reasonable to consider p53 as a critical regulator of angiogenesis through regulating HIF1a stability.
We and others have recently identi®ed a new p53 family member, termed p63/p51/p73L/p40/KET gene (Osada et al., 1998; Schmale and Bamberger, 1997; Senoo et al., 1998; Trink et al., 1998; Yang et al., 1998) . This gene, referred to as the p63 gene hereafter, encodes multiple isoforms with structural and functional similarities and dierences from p53. For example, TAp63g(p51A), an isoform harboring a transactivation domain at its amino-terminus, stimulates several previously identi®ed p53 target gene promoters such as p21 waf1/cip1 , mdm2 and bax (Dohn et al., 2001; Shimada et al., 1999; Osada et al., 1998; Yang et al., 1998) . It is also suggested that TAp63g induces apoptosis and growth suppression in a manner similar to p53 (Osada et al., 1998; Yang et al., 1998) . The p63 gene encodes another major isoform called dNp63a (p73L), an amino terminal-deleted isoform, which can potentially work as a dominant negative reagent toward both TAp63g and p53 (Yang et al., 1998; Senoo et al., 2001a,b) . Very recently, we and others have shown that the expression of TAp63g is frequently lacked and, in turn, dNp63a is more dominantly expressed in a variety of tumors compared to TAp63g (Crook et al., 2000; Hibi et al., 2000; Nylander et al., 2000; Park et al., 2000; Senoo et al., 2001a) . Unlike p53, the p63 gene is not frequently mutated in human cancers (Nishi et al., 1999; Park et al., 2000; Sunahara et al., 1999) . From these characteristics of p63, it is not unreasonable to speculate that TAp63g and dNp63a may play tumor suppressive and oncogenic properties, respectively.
In this study, we examined the possible roles of TAp63g and dNp63a in the regulation of VEGF expression. We show the evidence that VEGF expression was repressed by TAp63g, whereas it was conversely upregulated by dNp63a. We also show that these dual functions of the two p63 isoforms were closely correlated with their distinct functions in the regulation of HIF1a stability. These data point to two distinct regulatory VEGF pathways by the p63 gene products: a possible tumor suppressor signal by TAp63g suppressing VEGF, and an oncogenic one by dNp63a enhancing VEGF production.
Results

Repression by TAp63g and activation by dNp63a of VEGF expression
Since p53 is suggested to repress VEGF expression through inactivation of the VEGF gene promoter (Mukhopadhyay et al., 1995) , we examined potential eects of TAp63g (p51A) and dNp63a (p73L), the two major isoforms of the p53-related p63 gene, on the VEGF promoter activity (Figure 1 ). We cotransfected VEGF ± Luc bearing the promoter region 71217 to +370 (Shima et al., 1996) with wild-type p53, TAp63g or dNp63a expression vector into wild-type mouse embryonic ®broblast (MEF) cells and human nonsmall cell lung carcinoma-derived H1299 cells. As shown in Figure 1 , VEGF ± Luc reporter activity was decreased by more than 60% in the p53-transfected MEF and H1299 cells as compared to the vectortransfected cells. Although less signi®cant, VEGF ± Luc reporter activity was also decreased by approximately 40% in both TAp63g-transfected MEF and H1299 cells. In contrast, VEGF ± Luc reporter activity was surprisingly upregulated by more than 155% of the control in both dNp63a-transfected MEF and H1299 cells. The repression by TAp63g and activation by dNp63a of the VEGF ± Luc reporter activity were in a manner of dose-dependent (data not shown). H1299 cells harbor a homozygous deletion at the p53 gene locus (Mitsudomi et al., 1992) and does not express detectable amounts of endogenous p63 and p73 (Dohn et al., 2001) . Therefore, we speculate that transcriptional activation of the VEGF ± Luc reporter by dNp63a was not due to the dominant negative eect of dNp63a toward either endogenous p53 or transactivating versions of p73 and p63. Rather, we prefer to interpret that dNp63a may modulate some cellular factor(s) that are important in the regulation of VEGF promoter activity (see below).
To determine whether TAp63g and dNp63a substantially represses and activates endogenous VEGF expression, we established stable H1299 cell lines which inducibly express p53, TAp63g and dNp63a by CreloxP system upon infection with Cre-producing adenovirus AxCANCre (Figure 2a ). These cell lines showed equivalent cell growth and produced an Upon infection with AxCANCre, VEGF protein expression level was decreased by 49% and 23% in p53-and TAp63g-expressing cells as compared to the control cells, respectively (Figure 2b ). In contrast, VEGF protein expression level was conversely upregulated by 113% of the control level in dNp63a-expressing cells (Figure 2b ). This increase was relatively moderate but was statistically signi®cant (P50.05, t-test). Consistent with the transient transfection experiments using VEGF ± Luc reporter (Figure 1 ), these results suggest that TAp63g and dNp63a have negative and positive roles on endogenous VEGF expression, respectively, even under normoxic condition.
Identification of cis-acting element, necessary for p63-mediated modulation of VEGF promoter activity Next we focused on elucidating the mechanism(s) that TAp63g and dNp63a possess opposite eects on the VEGF gene expression. We ®rst investigated the responsible element(s) in the VEGF promoter for TAp63g-mediated repression and dNp63a-mediated upregulation. For this purpose we generated a series of VEGF promoter deletion mutants (Figure 3a) . We cotransfected these reporter constructs with either p63, TAp63g or dNp63a expression vector into H1299 cells. The result showed that dNp63a transactivated the fulllength VEGF ± Luc reporter but not VEGF ± Eco-Luc, VEGF ± Mlu-Luc and VEGF ± Sma-Luc that lacked 7976 to 7772, 71217 to 7449 and 71217 to +127, respectively ( Figure 3a ). This result suggests that nucleotides between 7976 and 7772 within the VEGF promoter are critical for dNp63a-mediated transcriptional upregulation. In contrast, both p53 and TAp63g repressed VEGF ± Luc, VEGF ± Eco-Luc and VEGF ± Mlu-Luc, but not VEGF ± Sma-Luc reporter activity. This result suggests that TAp63g possesses p53-like, although weaker, repressing eects on the VEGF promoter activity (see Discussion). However, consecutive removal of the region between 7976 and 7772 bp caused a partial decline in the repressing eect of TAp63g on VEGF promoter activity, ranging from 41%-inhibition in the VEGF ± Luc construct to 30%-inhibition in the VEGF ± Eco-Luc construct. In the case of p53, the repressing eect was ranged from 79%-inhibition of the VEGF ± Luc construct to 69%-inhibition in the VEGF ± Eco-Luc construct. These data, showing that repressing eects of TAp63g and p53 were similarly declined (*10%) by removal of nucleotides between 7976 and 7772 from the VEGF ± Luc construct, may suggest that both TAp63g and p53 may interfere with some common cellular factor(s) which bind to this region. Collectively, these results suggest that nucleotides between 7976 and 7772 within the VEGF promoter may be involved in the dual roles for dNp63a-mediated upregulation and a moderate repression by TAp63g.
Interestingly, a HIF1 binding site has been reported to exist in the region between 7917 and 7910 within the VEGF promoter ( Figure 3a , see Forsythe et al., 1996) . It has been shown that HIF1 regulates the VEGF gene expression (Wenger and Gassmann, 1997; Semenza, 1999) . Moreover, it has been shown that p53 represses VEGF promoter activity through targeting Figure 2 Eects of p53, TAp63g and dNp63a on VEGF production. (a) Characterization of cell lines that inducibly express HA-tagged p53, TAp63g and dNp63a by Cre-loxP system. The H1299 cell lines, which harbor pCALNL5 (lanes 1 and 2), pCAL ± p53 (lanes 3 and 4), pCAL ± TAp63g (lanes 5 and 6) and pCAL ± cNp63a (lanes 7and 8) were incubated in the absence (7) or presence (+) of AxCANCre for 1 h. Forty-eight hours post infection, whole cell extracts were subjected to Western blot analysis to determine the levels of p53, TAp63g and dNp63a with anti-HA antibody. (b) VEGF protein expression. Forty-eight hours post infection, the conditioned media prepared in (a) were collected and examined for VEGF protein expression by an ELISA assay. VEGF protein levels without infection with AxCANCre were set as 100% for each determination. Data are expressed as mean+s.d. of three independent experiments. *P50.05; **P50.01 (t-test) HIF1a for proteasome-dependent degradation (Ravi et al., 2000) . We therefore hypothesized that TAp63g and dNp63a oppositely modulate HIF1-dependent transcription, leading to repression and upregulation of the VEGF promoter activity, respectively. To address this possibility, another set of VEGF-reporter constructs was generated and was transiently transfected into H1299 cells together with either CMV ± TAp63g or CMV ± dNp63a. As shown in Figure 3b , HRE ± wt-Luc harboring nucleotides between 7927 and 7778 within the VEGF promoter was repressed and upregulated by TAp63g and dNp63a, respectively, to the similar extent of the parental VEGF ± Luc reporter ( Figure 3a ). In contrast, three base-pair substitution from CGT to AAA within the HIF1 binding site in the reporter construct (HRE ± mt-Luc) completely abolished both repression by TAp63g and upregulation by dNp63a ( Figure 3b ). This three base-pair substitution was previously reported to result in loss of HIF1 binding and therefore diminish HIF1-dependent transcription (Forsythe et al., 1996) . These results suggest that TAp63g and dNp63a oppositely modulate the VEGF 6 cells) were immunoprecipitated with anti-HA antibody and the resultant immune complexes were subjected to immunoblot analysis with anti-HIF1a monoclonal antibody (lanes 4 ± 6). Input refers to 5% of each whole cell lysate before immunoprecipitation (lanes 1 ± 3) Figure 5 Eects of p53, TAp63g and dNp63a expression on HIF1a stability. (a) Protein levels of HIF1a in the presence of p53, TAp63g and dNp63a. Cells were cotransfected with pCAG ± HIF1a (3.0 mg, lanes 2 ± 5) and 3.0 mg of the indicated plasmid. Aliquots of whole cell extract, prepared 40 h post transfection, were subjected to immunoblot analysis with a mixture of antiHIF1a antibody and anti-HA antibody. Lane 1: control lysate of the cells without transfection. (b) Proteasome-dependent degradation of HIF1a by TAp63g. Cells were transfected as in (a) and were treated with 20 mM MG132 for 12 h before lysis as indicated (lanes 2 and 4). Aliquots of whole cell extract were subjected to immunoblot analysis as in (a). (c) Stabilization of HIF1a by dNp63a. Cells were cotransfected with pCAG ± HIF1a (3.0 mg) and either pcDNA3 (3.0 mg, lanes 1 and 3) or pCMV ± dNp63a (3.0 mg, lanes 2 and 4). Twenty-four hours after transfection, the cells were incubated in the presence (+) or absence (7) of 100 mM cycloheximide (CHX) for 1 h before lysis. Aliquots of whole cell extract were subjected to immunoblot analysis as in (a). promoter activity through dierentially altering HIF1-dependent transcription.
Physical association of TAp63g and dNp63a with HIF1a
We next examined whether TAp63g and dNp63a physically interact with HIF1a as is the case with p53 (Ravi et al., 2000) . For this purpose, pCAG ± HIF1a was introduced into COS7 cells with either pCMV ± TAp63g or pCMV ± dNp63a. As shown in Figure 4 , immunoprecipitation with anti-HA antibody followed by immunoblot with anti-HIF1a antibody demonstrated that both TAp63g and dNp63a equally associated with HIF1a in the cells (lanes 5 and 6). This interaction was speci®c since HIF1a could not be detected in the immunoprecipitate from the control sample without TAp63g nor dNp63a (lane 4), even when three times more number of the transfected cells were subjected to this assay (compare lanes 1 and 3). This result suggests that both TAp63g and dNp63a physically interact with HIF1a in the cells.
TAp63g and dNp63a oppositely modulate HIF1a stability
It is notable that HIF1a protein amount was dierent between the whole cell lysates receiving TAp63g and dNp63a expression vectors (Figure 4, lanes 2 and 3) , despite of the similar association of HIF1a with TAp63g and dNp63a (lanes 5 and 6). Moreover, targeting of HIF1a by p53 is suggested to cause degradation of HIF1a through a proteasome-dependent pathway (Ravi et al., 2000) . Thus, we hypothesized that HIF1a stability is also regulated negatively by TAp63g, but positively by dNp63a. Again, HIF1a protein level was decreased in the cells coexpressing TAp63g as much as the cells coexpressing p53 as compared to the control cells ( Figure 5a, lanes 2, 3 and  4) . On the other hand, HIF1a protein level in the cells receiving pCMV ± dNp63a was comparable to or even slightly increased compared to that of control (lanes 2 and 5). These results suggest that TAp63g destabilizes HIF1a as is the case with p53, but that dNp63a may not possess such an eect.
To examine whether degradation of HIF1a by TAp63g is promoted in a proteasome-dependent manner, we examined another cotransfection experiment using a proteasome inhibitor (MG132). As shown in Figure 5b , treatment of cells with MG132 restored HIF1a protein level even in the presence of TAp63g (lanes 3 and 4) . This result suggests that proteasomedependent pathway is responsible, at least in part, to TAp63g-mediated degradation of HIF1a. , indicator plasmid (0.3 mg)+pGAL4 ± HIF1a (0.3 mg, lanes 2 ± 8), and additional plasmids as indicated: lanes 3 and 4, +pCMV ± p53 (0.1 mg and 0.3 mg, respectively); lanes 5 and 6, +pCMV ± TAp63g (0.1 mg and 0.3 mg, respectively); lanes 7 and 8, +pCMV ± dNp63a (0.1 mg and 0.3 mg, respectively) under normoxic condition (21% O 2 ). Cells were harvested for luciferase assay 48 h after transfection. Data are expressed as mean+s.d. of three independent experiments. (c) p300 and dNp63a collaboratively stimulate HIF1a-dependent transcription. H1299 cells were transiently transfected with PG5 ± Luc indicator plasmid (0.3 mg)+pGAL4 (0.3 mg) (lanes 1 ± 4), indicator plasmid (0.3 mg)+pGAL4 ± HIF1a (0.3 mg) (lanes 5 ± 8) and additional plasmids as indicated: lanes 2 and 6, +pCMV ± p300 (0.3 mg); lanes 3 and 7, +pCMV ± dNp63a (1.0 mg); lanes 4 and 8, +pCMV ± p300 (0.3 mg)+pCMV ± dNp63a (1.0 mg). Cells were harvested for luciferase assay 48 h after transfection. Data are expressed as mean+s.d. of three independent experiments p63 modulates VEGF expression M Senoo et al
To con®rm whether dNp63a contributes to stabilization of HIF1a, we examined the HIF1a level in the cells using a similar cotransfection experiment in the absence or presence of a protein synthesis inhibitor (CHX, cycloheximide). As shown in Figure 5c , HIF1a protein level was decreased to 50% of control within 1 h by CHX treatment in the absence of dNp63a (lanes 1 and 3) . However, the level of HIF1a was maintained at a higher degree (87%) by CHX treatment during the same period in the cells coexpressing dNp63a (lanes 2 and 4) . Although the precise mechanism should be clari®ed further, this result suggests that dNp63a, in contrast to p53 or TAp63g, contributes to stabilization of HIF1a.
To further examine the dual roles of TAp63g and dNp63a on endogenous HIF1a protein level, the cells which had received either CMV ± p53, CMV ± TAp63g or CMV ± dNp63a were incubated at 1% O 2 for 4 h before lysis (Figure 6a ). This treatment of the cells signi®cantly promoted accumulation of endogenous HIF1a protein compared to the cells maintained at 21% O 2 (lanes 1 and 2) . In this process, TAp63g repressed accumulation of HIF1a protein level similarly to the eect by p53 (lanes 3 and 4) . In contrast, dNp63a further enhanced accumulation of HIF1a protein under hypoxic condition (compare lanes 2 and 5). The decrease and increase in HIF1a levels were not accompanied by the substantial changes in HIF1a mRNA levels (Figure 6b ), indicating that modulation of HIF1a protein levels by TAp63g and dNp63a is due to a post-transcriptional mechanism.
Effects of TAp63g and dNp63a on HIFa-dependent transcription
The above data clearly demonstrated that TAp63g and dNp63a possess opposite eects on HIF1a stability (Figures 5 and 6 ). Then, it is of interest to determine how such distinct functions of TAp63g and dNp63a on HIF1a stability aect HIF1a-dependent transcription. To address this issue, we utilized mammalian two-hybrid assay, in which the construct harboring HIF1a cDNA was fused with GAL4 DNA binding domain (DBD) sequences and was introduced into H1299 cells in the absence or presence of increasing amounts of pCMV ± p53, pCMV ± TAp63g and pCMV ± dNp63a (Figure 7a) . The results showed that TAp63g decreased HIF1a-dependent transcription in a dose-dependent manner to a similar extent of those by p53 (Figure 7b , lanes 3 ± 6). In contrast, dNp63a was found to upregulate HIF1a-dependent transcription in a manner of dose-dependent (lanes 7 and 8). In this system, hypoxic treatment (1% O 2 ) of the transfected cells, the condition for upregulating HIF1a stability, further increased the HIF1a-dependent transcription (Figure 7b, left) , suggesting that exogenous GAL4 ± HIF1a is also involved in the stability control under this experimental system. In this point, these results are well consistent with the above ®ndings showing that TAp63g destabilizes HIF1a, while dNp63a targets HIF1a for stabilization (Figures 5 and 6 ). From these results, it is not unreasonable to speculate that TAp63g and dNp63a oppositely regulate HIF1a-dependent transcription through dierentially modulating HIF1a stability.
It is recently suggested that stabilized HIF1a exerts its transcriptional activity by recruiting a transcriptional coactivator p300/CBP (Kallio et al., 1998; Arany et al., 1996; Ema et al., 1999 ). Then we queried Figure 5 and the whole cell extracts were subjected to Western blot analysis 24 h after transfection with antibodies against HIF1a, p63 (for TAp63g and dNp63a) and HA-tag (for p53). (b) HIF1a-dependent transcription activity. Mammalian two-hybrid assays were performed as in Figure 7 with the indicated plasmids under normoxic (21% O 2 , open bars) and hypoxic (1% O 2 , solid bars) conditions. H1299 cells were transiently transfected with PG5 ± Luc indicator plasmid (0.3 mg)+pGAL4 (0.3 mg) (lane 1), indicator plasmid (0.3 mg)+pGAL4 ± HIF1a (0.3 mg, lanes 2 ± 6), and additional plasmids as indicated: lanes 3 and 4, +pCMV ± p53 (0.3 mg); lanes 5 and 6, +pCMV ± TAp63g (0.3 mg); lanes 4 and 6, +pCMV ± dNp63a (0.3 mg). Data shown are mean+s.d. from three independent experiments whether dNp63a and p300/CBP collaboratively upregulate HIF1a-dependent transcription. For this, we examined another set of mammalian two-hybrid experiments. As shown in Figure 7c , none of p300, dNp63a nor their combination upregulated the PG5 ± Luc reporter activity in conjunction with pGAL4 vector (lanes 1 ± 4) . In contrast, p300, dNp63a and the combination of the two were found to upregulate HIF1a-dependent transcription over the control level by 44, 38 and 87%, respectively (lanes 6 ± 8). This additive contribution by p300 and dNp63a on HIF1a-dependent transcription suggest that dNp63a and p300/ CBP collaboratively upregulate HIF1a-dependent transcription and that stabilized HIF1a by dNp63a may take advantage of recruiting p300/CBP in promoting downstream gene expression.
Dominant-negative activities of dNp63a toward p53-and TAp63g-dependent down-regulation of the stability and transactivating function of HIF1a dNp63a is shown to act as a dominant-negative reagent toward both p53 and TAp63g through competing binding to the same target DNA sequences (Yang et al., 1998; Senoo et al., 2001b) . To our knowledge, however, mutual activities among these three molecules on the same target protein are not reported so far. Therefore, we asked whether dNp63a possesses dominant-negative activities toward p53-and TAp63g-dependent down-regulation of HIF1a protein.
As shown in Figure 8a , dNp63a could rescue p53-and TAp63g-dependent down-regulation of the HIF1a protein level in COS7 cells even under normoxic condition (lanes 4 and 6). Consistent with this notion, dNp63a restored p53-and TAp63g-mediated downregulation of HIF1a-dependent transcription in H1299 cells (Figure 8b , lanes 4 and 6) both under normoxic and hypoxic conditions, although they did not reach to the control level (lane 2). Collectively, these data would suggest that dNp63a may partially reverse p53-and TAp63g-mediated inhibition of HIF1-dependent transcription by preventing their association with HIF1a.
Discussion
The p63 gene, recently identi®ed as a tumor suppressor p53 relative, encodes multiple isoforms with structural and functional similarities and dierences from p53. In human tumors, p63 is not frequently mutated like p53, but certain isoforms are occasionally lacked or overexpressed (Crook et al., 2000; Hibi et al., 2000; Nylander et al., 2000; Park et al., 2000; Senoo et al., 2001a) . It is known that p53 represses VEGF expression (Bouvet et al., 1998; Fontanini et al., 1998; Mukhopadhyay et al., 1995) , which is considered to be a critical regulator for tumor growth. In this study, we have investigated functional roles of p63 on VEGF expression. Our data showed that TAp63g and dNp63a, the two major isoforms of p63, oppositely regulate the VEGF gene expression on transcription and protein level, and that HIF1a protein which regulates the VEGF promoter activity is highly degraded by TAp63g but rather protected by dNp63a.
Among TAp63g, dNp63a and p53, only dNp63a upregulated VEGF ± Luc activity and others repressed both in the p53-null cell line H1299 and in normal diploid cells carrying endogenous p53 to the similar extent (Figure 1 ). This suggests that endogenously expressed wild-type p53 does not signi®cantly aect p63-mediated modulation of the VEGF gene expression, although involvement of mutant p53 should be clari®ed further.
With use of deletion mutants of VEGF ± Luc, we showed that the promoter region 7976 to 7772 is critical for dNp63a-mediated upregulation on the promoter activity. In comparison, the same region seems to be partially responsible for TAp63g-mediated repression of the VEGF-promoter activity because TAp63g still moderately impaired the VEGF ± Mluluc that lacks the promoter region 7976 to 7772 (Figure 3a ). In the cases of p53 and its homolog p73 which possess the similar tumor suppressive functions as TAp63g, some potential Sp1 binding sites in the 785 to 750 promoter region were reported to be involved in repression of VEGF expression (Mukhopadhyay et al., 1995; Salimath et al., 2000) . In addition, we have recently shown that TAp63g represses epidermal growth factor receptor (EGFR) expression through interacting with Sp1 and impairing its DNA binding ability (Nishi et al., 2001 ). Therefore, it is possible to speculate that repression of VEGF expression by TAp63g also results from the interaction between TAp63g and Sp1. This speculation would make it possible to explain why TAp63g repressed VEGF ± Mlu-Luc but not VEGF ± Sma-Luc as was the case with p53 (Figure 3a) .
In the region between nucleotides 7976 and 7772 within the VEGF promoter, there is a HIF1 binding site between 7917 and 7910 (Figure 3a) . HIF1a binds to the target DNA site in conjunction with HIF1b and consequently leads to transcriptional activation of the downstream genes including the VEGF gene (for review see Semenza, 1999; Wenger and Gassmann, 1997) . In this study, we showed that the mutation in the HIF1 binding site results in loss of dual functions by TAp63g and dNp63a on the reporter activity (Figure 3b) . Moreover, our study also demonstrated that HIF1a-dependent transcriptional activity is repressed by TAp63g as suggested by p53 (Blagosklonny et al., 1998) , but is upregulated by dNp63a (Figure 7b ). In addition, the upregulation of VEGF promoter activity by dNp63a was markedly enhanced by addition of exogenous HIF1 or by hypoxic stimuli (data not shown). Thus, it is suggested that TAp63g and dNp63a oppositely regulate VEGF promoter activity through dierentially modulating HIF1a activity. At the same time, our results provide the ®rst suggestive evidence that TAp63g and p53 have similar negative eects on HIF1a activity (Figure 7b) .
At the molecular level, it has been reported that p53 represses VEGF promoter activity by proteasomedependent degradation of HIF1a (Ravi et al., 2000) .
In the present study, we showed that treatment of the TAp63g-transfected cells with a proteasome inhibitor signi®cantly upregulated HIF1a protein level ( Figure  5b , lane 4), suggesting that degradation of HIF1a by TAp63g employs a proteasome-degradation pathway as is the case with p53 (Ravi et al., 2000) . To our surprise, however, dNp63a was found to upregulate the stability of both exogenously expressed and endogenous HIF1a (Figures 5c and 6a ). This stabilization of HIF1a by dNp63a might result, at least in part, in upregulation of HIF1a-dependent transcription (Figure 7b) , and also may contribute to recruiting p300/CBP in promoting downstream gene expression (Figure 7c) . Since the expression level of HIF1a mRNA was not aected by forced expression of either TAp63g or dNp63a ( Figure  6b ), these two p63 isoforms may be substantially involved in the post-translational regulation of HIF1a but not in its transcription. Though proteasomal degradation of HIF1a is known to be prevented in response to hypoxia, the precise mechanism of HIF1a accumulation in tumors without accelerated transcription is remained unclear (Folkman, 1997; Zong et al., 1999) . Considering the recent studies including ours (Crook et al., 2000; Hibi et al., 2000; Nylander et al., 2000; Park et al., 2000; Senoo et al., 2001a) , the present study implicate that either decreased expression of TAp63g or increased expression of dNp63a in tumors may contribute to accumulation of HIF1a in tumors. In addition, our data have some implications that overexpression of dNp63a might act in a dominantnegative manner toward both p53-and TAp63g-mediated inhibition of HIF1a-dependent transcription (Figure 8 ). In this point of view, it would be interesting to examine the possible correlation between expression pro®le of the p63 isoforms and HIF1-dependent gene expression in tumors. Besides the VEGF gene, critical cis-acting DNA sequences that contain essential HIF1 binding sites have been identi®ed in other hypoxia-inducible genes, including erythropoietin (EPO), transferrin, inducible nitric oxide synthase (iNOS), heme oxygenase 1 (HO1), glucose transporter 1 (GLUT1), and glycolytic enzyme genes (Bunn and Poyton, 1996; Semenza, 1998; Wenger and Gassmann, 1997) . It might be useful, therefore, to investigate whether TAp63g and dNp63a are involved in the regulation of such genes to better understand the physiological roles of these two proteins in the regulation of HIF1-dependent transcription.
In summary, our present data show for the ®rst time that p63 is involved in the regulation of the VEGF gene expression and that modulation of VEGF expression by TAp63g and dNp63a is closely correlated with their distinct roles in the regulation of HIF1a stability. These data would further support the hypothesis that TAp63g and dNp63a possess a tumor suppressive and an oncogenic property, respectively. Although a variety of genes exist that are transcriptionally regulated by HIF1, the identi®cation of such gene(s) that are modulated in a p63 isoforms-speci®c manner will be the next major contribution to understanding p63-mediated tumorigenesis.
Materials and methods
Plasmids
Expression vectors, pCMV ± p53, pCMV ± TAp63g and pCMV ± dNp63a were described previously (Senoo et al., 2001a) . The full coding region of HIF1a from pcD ± HIF (a gift from GL Semenza, The John Hopkins University) was subcloned into BamHI site of pBIND (Promega) and EcoRI site of pCAGGS (Niwa et al., 1991) to generate pGAL4 ± HIF1a and pCAG ± HIF1a, respectively. The VEGF ± Luc reporter construct (Shima et al., 1996) and pCMV ± p300 were provided by PA D'Amore (Harvard Medical School) and S Ishii (RIKEN), respectively. VEGF ± Eco-Luc, VEGF ± Mlu-Luc and VEGF ± Sma-Luc were generated by removing the EcoO109I-, MluI-and SmaI-fragment, respectively, from the parental VEGF ± Luc construct and selfligated. HRE ± wt-Luc and HRE ± mt-Luc were generated by PCR-based mutagenesis using the parental VEGF ± Luc as a template. pCAL ± p53, pCAL ± TAp63g and pCAL ± dNp63a were generated by insertion of HA-tagged mouse p53, TAp63g and dNp63a cDNAs into a SmaI site of pCALNL5, which is a polylinker-inserted derivative from pCALNLw (Kanegae et al., 1996) .
Cell lines and culture
COS7 cells (an African green monkey kidney cell line), H1299 cells (a human non-small cell lung carcinoma cell line) and mouse embryonic ®broblast cells (prepared from C57BL/6 mouse embryos at E14.5) were cultured in Dulbecco's modi®ed Eagle's medium supplemented with 10% fetal bovine serum in a 378C humidi®ed atmosphere containing 5% CO 2 . For generating the stable H1299 cell lines upon infection by cre-expressing adenovirus AxCANCre (Kanegae et al., 1995) , the parent H1299 cells were stably transfected with pCAL ± p53, pCAL ± TAp63g and pCAL ± dNp63a. Subsequently, the cells were exposed to G418 (4 mg/ml) for 2 weeks and the independent clones were isolated, which were then maintained in the presence of 0.4 mg/ml of G418. Multiple clones showed similar pro®le in terms of growth rate and protein expression without infection by AxCANCre (data not shown).
Analysis of reporter activity
Cells were seeded into 12-or 24-well plate at a density of 1 ± 2610 5 cells/well the day before transfection. The cells were transfected with an appropriate amount of the expression plasmids along with 0.1 mg/well of pRLTK (Promega) by TransFast reagent (Promega). For mammalian two-hybrid assays, PG5 ± Luc (Promega) was used as an indicator plasmid. In all the transfection experiments, an empty vector pcDNA3 (Invitrogen) was used to adjust a total amount of DNA per well. The luciferase activity was analysed as described previously (Senoo et al., 2001a) .
Immunoblot analyses
Cell lysates were prepared 24 ± 48 h post transfection or adenovirus infection, fractionated by SDS ± PAGE, transferred to nylon membranes (Trans-Blot, BioRad), and immunoblotted with antibodies against HIF1a (OZ12, NeoMarkers), HA-tag (MBL, Japan) and p63 (4A4, Pharmingen). Equal protein loading and transfer was veri®ed by Ponceau staining (Sigma).
ELISA
The cells were infected by approximately 10 m.o.i (multiplicity of infection) of AxCANCre, and seeded into a 6-well plate at a density of 1610 5 cells/well. Quantikine (R & D Systems) was used to measure VEGF protein in supernatant medium of the cells 48 h after viral infection.
Northern blot analysis
Ten micrograms of total RNA, extracted by ISOGEN (Nippon Gene, Tokyo, Japan), was subjected to 1.0% agarose gel electrophoresis and the blot was hybridized with a full-length human HIF1a cDNA probe.
